Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis |
| |
| Authors: | Erin Dodd BA Kristen Hook MD |
| |
| Institution: | 1. Medical School, University of Minnesota, Minneapolis, Minnesota;2. Department of Dermatology, University of Minnesota, Minneapolis, Minnesota;3. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota |
| |
| Abstract: | Although topical steroids are considered first‐line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16‐month‐old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5% topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow‐up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children. |
| |
| Keywords: | |
|
|
